氟尿嘧啶缓释植入剂治疗恶性体腔积液的临床观察  

The clinical observation of fluorouracil sustained-release implants in the treatment of malignant body cavity fluid

作　　者：杨扬[1] 陈振东[1] 吴秀伟[1] 叶瑞萍[1] 孙昕[1] 

机构地区：[1]安徽医科大学第一附属医院,安徽合肥230022

出　　处：《山东医药》2009年第12期12-14,共3页Shandong Medical Journal

基　　金：安徽省科技攻关计划资助项目(060131227B)

摘　　要：目的观察缓释氟尿嘧啶植入剂对恶性体腔积液的治疗效果和对患者生活质量的影响。方法选取恶性体腔积液患者52例,予以缓释氟尿嘧啶植入剂(中人氟安)800 mg/m2体腔内化疗。评价其疗效及毒副反应。并观察不同病种、基线KPS评分、肿瘤标志物、细胞学等对疗效的影响。结果恶性体腔积液的总缓解率为52%,其中卵巢癌腹水缓解率为67%,明显高于其他类型肿瘤所致。积液细胞学检查阳性者缓解率为66%,亦明显高于细胞学阴性者。而基线KPS评分,肿瘤标志物对疗效均无明显影响。患者治疗后KPS评分明显提高,治疗未加重患者的疲劳程度。所有患者均未发生明显的毒副作用。结论缓释氟尿嘧啶植入剂体腔化疗治疗恶性体腔积液可取得较好的临床疗效,特别是对卵巢癌腹水效果尤佳。Objective TO observe the effect of fluorouracil sustained-release implants on malignant body cavity fluid and patient＇ s.quality of life（QOL）. Methods 52 patients with malignant body cavity fluid were investigated. The treatment effect was assessed with Millar JW＇ s evaluation criteria for malignant body cavity fluid. QOL was assessed with Fatigue Symptom Inventory（FSI） and Karnofsky performance score （KPS）. The incidence of chemotherapy toxicity was assessed with CTCAE3.0. The influence of treatment effect with original disease, base-line KPS, tumor marker（TM） and cytology was observed. Results The total Remission rate was 52 %. The remission rate of ovarian cancer ascites was 67% which was obviously higher than others（ P = 0.038 ）. The remission rate of patients whose fluid cytology positive was 66%, higher than others as well（ P = 0.028 ）. Nevertheless, base-line KPS and TM had no influence on the treatment effect. The KPS of patients had a distinct improvement and treatment did not increase the patient＇ s level of fatigue. There was no apparent toxicity in all patients who entered the study. Conclusion Fluorouracil sustained-release implants in the treatment of malignant body cavity fluid may have a better clinical effect, especially in ovarian cancer patients.

关 键 词：胸腔积液 恶性 氟尿嘧啶 缓释剂 植入剂 

分 类 号：R730.5[医药卫生—肿瘤]